Figure 3.

Analysis of the immune system commitment during the clinical follow-up of the patient co-infected with visceral leishmaniasis and human immunodeficiency virus (HIV). The patient was evaluated at the time of the first episode of visceral leishmaniasis (active phase), one month after antileishmanial therapy (post-therapy), during the period without signs or symptoms of leishmaniasis (clinical remission), and during relapses (reactivation). A, Absolute counts of circulating CD4⁺ T lymphocytes/mm³ and HIV viral load (RNA copies/mL). B, Population of CD8⁺ T lymphocytes expressing CD38 molecules. C, Population of CD3⁺ T lymphocytes expressing HLA-DR molecules.